Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results

Century Therapeutics (NASDAQ:IPSC) issued its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.12, Zacks reports. Century Therapeutics had a negative net margin of 9,742.41% and a negative return on equity of 59.74%. The firm had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.55 million.

Century Therapeutics Stock Performance

Shares of NASDAQ IPSC traded down $0.08 during trading on Friday, hitting $1.72. 272,387 shares of the company traded hands, compared to its average volume of 215,346. The firm has a market capitalization of $145.34 million, a price-to-earnings ratio of -0.78 and a beta of 1.39. The business’s fifty day moving average is $2.58 and its 200 day moving average is $3.40. Century Therapeutics has a fifty-two week low of $1.28 and a fifty-two week high of $5.51.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on IPSC shares. Piper Sandler boosted their target price on shares of Century Therapeutics from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Monday, June 17th. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Century Therapeutics in a research note on Tuesday, June 4th. Finally, Rodman & Renshaw began coverage on Century Therapeutics in a research report on Thursday. They set a “buy” rating and a $6.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $11.60.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.